APOH

DENVER, Aug. 26 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation , a worldwide developer and marketer of diagnostic test kits, has announced its collaboration with BG Medicine (BGM) a Waltham, Mass.-based life sciences company focused on the discovery, development and commercialization of novel molecular-based diagnostics. Under the collaboration, Corgenix' AtherOx(R) products will be included in studies conducted by BG Medicine to predict near-term risk of first myocardial infarction (MI). "We are extremely pleased with this opportunity to evaluate the role of our AtherOx products in this important indication," said Douglass Simpson, Corgenix' President and Chief Executive Officer. Under the terms of the collaboration agreement, Corgenix will provide several of its products for the studies conducted by BG Medicine, including the IgG Anti-AtherOx(R) Kit, which is currently FDA cleared, as well as the investigational Anti-AtherOx IgM and AtherOx kits. Corgenix may use the data generated by BG Medicine with the AtherOx technology products for regulatory and commercialization purposes in exchange for certain considerations. The IgG Anti-AtherOx Test Kit indication for use in the United States is for the detection of IgG antibodies to complexes formed by oxidized low-density lipoprotein (oxLDL) with B2-glycoprotein I (B2GPI) in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (antiphospholipid syndrome). About Corgenix Medical Corporation Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at About AtherOx The AtherOx technology utilizes oxidized low-density-lipoprotein (oxLDL) complexed with the plasma protein B2GPI. Although oxLDL has been implicated in cardiovascular disease, according to results published in the Annals of N.Y. Academy of Science (2007), determination of oxLDL/B2GPI complexes, rather than oxLDL alone, may be a more physiologic and accurate way of assessing the risk of progressive atherosclerotic cardiovascular disease in individuals with systemic lupus erythematosus and lupus-like disorders. Corgenix licensed this technology in 2002, and is developing additional products utilizing this unique platform. Two U.S. patents have been issued and several others are pending. Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements. CONTACT: William Critchfield, Senior VP and CFO of Corgenix Medical Corp., +1-303-453-8903, wcritchfield@corgenix.com; or Media, Dan Snyders, Vice President and Public Relations Supervisor of Armada Medical Marketing, +1-303-623-1190, ext. 230, Fax, +1-303-623-1191, dan@armadamedical.com, for Corgenix Medical Corp. Web site: